Bristol-Myers Squibb Company
NYSE: BMY
$58.00
+$0.24 (+0.4%)
Closing Price on December 26, 2024
BMY Articles
September 28, 2016: Here are four stocks trading with relatively heavy volume among 33 equities making new 52-week lows in Wednesday’s session. NYSE advancers led decliners by nearly 7 to 3 and...
Published:
Last Updated:
The September 15 short interest data have been compared with the previous figures, and for most of the selected pharmaceutical stocks, short interest has increased.
Published:
Last Updated:
Despite recent market headwinds and volatility, there are strong underlying fundamentals among the large cap pharmaceuticals that are continuing to drive them forward.
Published:
Last Updated:
The August 31 short interest data have been compared with the previous figures, and for most of the selected pharmaceutical stocks, short interest has significantly decreased.
Published:
Last Updated:
September 12, 2016: Here are four stocks trading with relatively heavy volume among 56 equities making new 52-week lows in Monday’s session. NYSE advancers led decliners by more than 2 to 1 and...
Published:
Last Updated:
September 2, 2016: Here are four stocks trading with relatively heavy volume among 21 equities making new 52-week lows in Friday’s session. NYSE advancers led decliners by nearly 4 to 1 and Nasdaq...
Published:
Last Updated:
The August 15 short interest data have been compared with the previous figures, and for most of the selected pharmaceutical stocks, short interest has significantly decreased.
Published:
Last Updated:
The July 29 short interest data have been compared with the previous figures, and for most of the selected pharmaceutical stocks, short interest was lower.
Published:
Last Updated:
Credit Suisse sees the Bristol-Myers Squibb gap with Merck getting even worse, even though it still has robust I-O franchise estimates for Bristol-Myers.
Published:
Last Updated:
The top analyst upgrades, downgrades and initiations seen on Monday morning include BlackRock, Bristol-Myers, Level 3, NVIDIA, Monsanto and Twenty-First Century Fox.
Published:
Last Updated:
Bristol-Myers Squibb shares took a nosedive early Friday's following an update in its late-stage Checkmate trial. But Bristol-Myer's failure was a big win for Merck.
Published:
Last Updated:
Bristol-Myers Squibb released a better-than-expected second-quarter earnings report before the markets opened on Thursday.
Published:
Last Updated:
The short interest data have been released for the July 15 settlement date. For the selected pharmaceutical stocks, short interest was mixed.
Published:
Last Updated:
SunTrust Robinson Humphrey feels that the major pharmaceutical companies will outperform the rest of the year, and they cite new products, attractive dividends and solid performance as positives.
Published:
Last Updated:
The June 30 short interest data have been compared with the previous figures, and for the selected pharmaceutical stocks short interest decreased.
Published:
Last Updated: